本文選題：胃腺癌 + Nanog��； 參考：《河北大學(xué)》2017年碩士論文

【摘要】：胃癌是世界第二大致死惡性腫瘤,而其中胃腺癌又占95%以上。在中國(guó),胃腺癌具有高發(fā)病率和高死亡率,病人的五年存活率非常低,因此胃腺癌是中國(guó)嚴(yán)重的公共衛(wèi)生問(wèn)題,也是中國(guó)醫(yī)學(xué)急需解決的問(wèn)題之一。本研究探究了 miR-199b-5p與干細(xì)胞標(biāo)志物Nanog及胃癌腫瘤干細(xì)胞標(biāo)志物CD44之間的關(guān)系,旨在深入了解miRNA對(duì)腫瘤以及腫瘤干細(xì)胞的調(diào)節(jié)作用,并且對(duì)胃腺癌腫瘤干細(xì)胞和腫瘤細(xì)胞進(jìn)行轉(zhuǎn)錄組測(cè)序篩選出來(lái)差異表達(dá)的miRNA,為治療胃腺癌提供新的分子靶標(biāo)和研究思路。我們通過(guò)腫瘤細(xì)胞測(cè)序和生物信息學(xué)方法,預(yù)測(cè)出了 miR-199b-5p的靶向序列位于Nanog和CD44的3'UTR區(qū)域,可能存在抑制NANOG和CD44蛋白表達(dá)的情況。實(shí)驗(yàn)部分主要通過(guò)在胃腺癌細(xì)胞系MGC803中過(guò)表達(dá)miR-199b-5p以觀察其對(duì)Nanog和CD44基因表達(dá)及蛋白翻譯水平的影響。結(jié)果說(shuō)明miR-199b-5p對(duì)Nanog沒(méi)有影響,而CD44的表達(dá)在miR-199b-5p過(guò)表達(dá)的MGC803細(xì)胞中明顯降低,這一結(jié)果提示miR-199b-5p可抑制CD44基因的表達(dá)。通過(guò)在MGC803細(xì)胞中過(guò)表達(dá)miR-199b-5p,觀察miR-199b-5p對(duì)胃腺癌細(xì)胞生物學(xué)功能的影響。研究發(fā)現(xiàn),miR-199b-5p上調(diào)能顯著抑制胃腺癌細(xì)胞MGC803的增殖、遷移、侵襲及耐藥程度。這些實(shí)驗(yàn)表明,miR-199b-5p可以作為抑癌基因,抑制腫瘤的發(fā)生、遷移、侵襲和耐藥。miR-199b-5p的細(xì)胞生物學(xué)作用可能與其抑制CD44相關(guān)。我們的結(jié)論是:miR-199b-5p是一個(gè)潛在的對(duì)腫瘤干細(xì)胞標(biāo)志物CD44具有調(diào)節(jié)作用的miRNA,通過(guò)抑制CD44從而抑制一系列腫瘤細(xì)胞生物學(xué)活性。這為胃腺癌腫瘤干細(xì)胞標(biāo)志物CD44信號(hào)通路的研究拓寬了基礎(chǔ),也為腫瘤的診斷和治療提供給了新的分子靶標(biāo)。然而,值得注意的是,miR-199b-5p在我們的實(shí)驗(yàn)結(jié)果中表明可以抑制癌癥的發(fā)生和發(fā)展,但是我們通過(guò)smallRNA測(cè)序結(jié)果來(lái)看,miR-199b-5p在類(lèi)腫瘤干細(xì)胞中的表達(dá)遠(yuǎn)遠(yuǎn)高于腫瘤細(xì)胞。我們目前只能猜測(cè)這與細(xì)胞對(duì)抗腫瘤的自救效應(yīng)或者ceRNA調(diào)控有關(guān),而進(jìn)一步的研究需要通過(guò)實(shí)驗(yàn)證實(shí)。
[Abstract]:Gastric cancer is the second leading malignant tumor in the world, in which gastric adenocarcinoma accounts for more than 95%. In China, gastric adenocarcinoma has a high incidence and high mortality, and the 5-year survival rate of patients is very low. Therefore, gastric adenocarcinoma is a serious public health problem in China and one of the urgent problems to be solved in Chinese medicine. This study explored the relationship between miR-199b-5p and stem cell marker Nanog and gastric cancer tumor stem cell marker CD44 in order to understand the regulatory effect of miRNA on tumor and tumor stem cells. The differentially expressed miRNAs were screened by transcriptome sequencing from gastric adenocarcinoma tumor stem cells and tumor cells, which provided a new molecular target and research idea for the treatment of gastric adenocarcinoma. By means of tumor cell sequencing and bioinformatics, we predicted that the target sequence of miR-199b-5p is located in the 3'UTR region of Nanog and CD44, which may inhibit the expression of NANOG and CD44. The effect of miR-199b-5p on the expression of Nanog and CD44 gene and protein translation was observed by overexpression of miR-199b-5p in gastric adenocarcinoma cell line MGC803. The results showed that miR-199b-5p had no effect on Nanog, but the expression of CD44 was significantly decreased in MGC803 cells with miR-199b-5p overexpression, which suggested that miR-199b-5p could inhibit the expression of CD44 gene. The effect of miR-199b-5p on the biological function of gastric adenocarcinoma cells was observed by overexpression of miR-199b-5pin MGC803 cells. It was found that the upregulation of miR-199b-5p could significantly inhibit the proliferation, migration, invasion and drug resistance of gastric adenocarcinoma cell line MGC803. These results suggest that miR-199b-5p may act as a tumor suppressor gene, inhibit tumorigenesis, migration, invasion and cell biology of drug-resistant .miR-199b-5p, and may be related to its inhibition of CD44. Our conclusion is that: miR-199b-5p is a potential regulator of CD44, a tumor stem cell marker, which inhibits the biological activity of a series of tumor cells by inhibiting CD44. The results provide a new molecular target for the diagnosis and treatment of gastric adenocarcinoma. However, it is worth noting that the expression of miR-199b-5p in tumor-like stem cells is much higher than that in tumor-like stem cells by smallRNA sequencing. We can only speculate that this is related to the cellular antitumor self-rescue effect or ceRNA regulation, and further research needs to be confirmed by experiments.
【學(xué)位授予單位】：河北大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 楊澄;蘇宏偉;任慧文;李宏偉;;miR-199b-5p在骨肉瘤中的預(yù)測(cè)和診斷作用[J];中國(guó)輻射衛(wèi)生;2014年03期

2 陸國(guó)玉;吳曉飛;周蕾;俞嵐;武世伍;;CD133和CD44在胃腺癌中的表達(dá)及其與E-cadherin的關(guān)系[J];南方醫(yī)科大學(xué)學(xué)報(bào);2013年11期

3 王軍;張勇;任芳;張鳳春;;干細(xì)胞標(biāo)志物CD44與胃癌臨床病理特征的相關(guān)性研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2013年03期

4 Zhaode Bu;Zhixue Zheng;Lianhai Zhang;Ziyu Li;Yu Sun;Bin Dong;Aiwen Wu;Xiaojiang Wu;Xiaohong Wang;Xiaojing Cheng;Xiaofang Xing;Yingai Li;Hong Du;Jiafu Ji;;LGR5 is a promising biomarker for patients with stage Ⅰ and Ⅱ gastric cancer[J];Chinese Journal of Cancer Research;2013年01期

5 方興貴;郭平;;CD_(44)在腫瘤干細(xì)胞的研究進(jìn)展[J];醫(yī)學(xué)綜述;2012年20期

6 Ismail Gomceli;Baris Demiriz;Mesut Tez;;Gastric carcinogenesis[J];World Journal of Gastroenterology;2012年37期

7 Alba Rocco;Debora Compare;Gerardo Nardone;;Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions[J];World Journal of Gastrointestinal Oncology;2012年03期

8 周志華;張建東;徐桂芳;趙海濱;;基于克隆形態(tài)分選胃癌干細(xì)胞及其對(duì)氟尿嘧啶敏感性的檢測(cè)[J];中華胃腸外科雜志;2013年04期

，

本文編號(hào)：1807798